For Investors

View Main Content

WHO WE ARE

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

STOCK INFORMATION

Latest financial results

Q1 2025

Quarter Ended Jun 30, 2024

Latest annual filing

For Fiscal Year Ending Mar 31, 2024

INVESTOR CONTACTS

Company

Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018

Investor Relations

Immunovant, Inc.
Investor Relations
info@immunovant.com

Transfer Agent

Continental Stock Transfer & Trust Company, LLC
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000
cstmail@continentalstock.com